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Abstract Gingipains are the major cysteine proteinases synthe-
sized by Porphyromonas gingivalis which, in soluble form, are
able to initially convert IL-8 (77 amino acid residues) to a more
potent species truncated at the amino terminus, followed by slow
degradation and destruction of chemokine biological activity. In
contrast, the same enzymes when associated with bacterial outer-
membrane blebs (vesicles), instantly degrade this chemokine.
This division of enhancing and inactivating activity between
soluble and membrane-bound gingipains can cause the compart-
mentalization of pro- and anti-inflammatory reactions to distal
and proximal positions from bacterial plaque, respectively, which
may explain why, despite the massive neutrophil accumulation at
periodontitis sites, there is no elimination of infection.
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1. Introduction
Interleukin-8 (IL-8) is a pro-in£ammatory polypeptide be-
longing to the C-X-C family of chemokines [1,2] and is one of
the most potent activators of neutrophils. This cytokine is
produced by a variety of cell types including lymphocytes,
monocytes, endothelial cells, ¢broblasts, keratinocytes, epithe-
lial cells and neutrophils. In addition to chemotactic activity,
IL-8 has been shown to trigger both neutrophil degranulation
and the respiratory burst, enhance phagocytosis, and cause
the expression of CR1 and CR3 receptors on neutrophils
[3^7]. While IL-8 derived from monocytes and T lymphocytes
is predominantly a polypeptide of 72 amino acid residues (IL-
8-72), non-immunological cells secrete a 77-residues form (IL-
8-77) which is extended at the amino terminus. This form of
IL-8 has signi¢cantly lower biological activity which can be
enhanced by removal of the ¢rst 5^7 residues [2,4,8,9].
It is generally accepted that IL-8 is one of the major chemo-
tactic factors responsible for neutrophil migration towards
in£ammatory foci [10]. For this reason it may also play a
role in the in£ux of neutrophils into periodontal lesions dur-
ing outbreaks of periodontitis, an in£ammatory disease initi-
ated by speci¢c bacterial species residing in the subgingival
plaque [11,12]. A common histological hallmark of periodon-
titis is a massive accumulation of neutrophils in the gingival
connective tissue, the junctional epithelium and the periodon-
tal pocket at the site of infection [13,14]. While factors respon-
sible for this state are not fully understood, recent studies
have shown that IL-8 expression in periodontal tissue can
either be directly stimulated by LPS isolated from periodon-
topathogens or by other proin£ammatory cytokines, including
TNF-K and IL-1L, generated locally in response to this bac-
terial cell wall component [15^17].
In addition to the LPS-induced pathways of cytokine gen-
eration, pathogenic bacteria have developed various mecha-
nisms which can alter cytokine activity at the infection site,
and it is now clearly recognized that proteinases released by
pathogens do signi¢cantly a¡ect cytokine signaling networks
[18]. This applies particularly to the major periodontopatho-
gen, Porphyromonas gingivalis, an anaerobic bacterium which
is known to produce large quantities of proteolytic enzymes
with activity against a broad range of host proteins, including
cytokines [18,19]. Among the numerous proteinases released
by this organism, cysteine proteinases with Arg-Xaa or Lys-
Xaa speci¢city, referred to as gingipain R and gingipain K,
respectively, are recognized as important virulence factors be-
cause they appear to contribute signi¢cantly to the pathogen-
esis of periodontitis [20,21]. In this report we have studied the
e¡ect of these gingipains on IL-8 biological activity, because
this cytokine is likely to play an important role in neutrophil
accumulation at periodontitis sites.
2. Materials and methods
2.1. Reagents
Percoll, cytochalasin B, and N-methoxysuccinyl-Ala-Ala-Pro-Val-
pNA were obtained from Sigma, while leupeptin, E-64, and DIC
(3,4-dichloroisocoumarin) were purchased from Boehringer Mann-
heim Biochemicals (Indianapolis, IN, USA). ZFKck (benzyloxycar-
bonyl-Phe-Lys-CH2OCP-2,4,6-Me3-Ph) and FPRck (Phe-Pro-Arg-
chloromethylketone) were obtained from Bachem Biosciences (Phila-
delphia, PA, USA). The 50-kDa gingipain R (RgpB), 95-kDa gingi-
pain R (RgpA), and gingipain K (Kgp) were puri¢ed from P. gingi-
valis as previously described [22,23], as were vesicle fractions [24].
2.2. Chemokines and antibodies
Both recombinant endothelial type IL-8-77 and monocyte IL-8-72
were purchased from BioSource International. Polyclonal antibodies
against human recombinant IL-8 and goat anti-rabbit IgG conjugated
with horseradish peroxidase were obtained from Genzyme (Cam-
bridge, MA, USA) and Pierce Biochemicals (Rockford, IL, USA),
respectively.
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2.3. Proteolytic degradation of IL-8 by puri¢ed gingipains
Gingipains were activated in 200 mM HEPES, 5 mM CaCl2, pH
7.6, 10 mM cysteine, for 5 min at 37‡C, then mixed with IL-8-77 in
the same bu¡er at an E/S molar ratio of 1:550 (¢nal enzyme concen-
tration 10 nM), and incubated at 37‡C. At designated time points
aliquots were removed and enzyme activity terminated by addition
of leupeptin (0.5 WM ¢nal concentration) or Z-FK-ck (0.5 WM ¢nal
concentration) to the Rgp or Kgp digests, respectively. Part of the
reaction mixture was used to assay for IL-8 biological activity, and
the remainder was analyzed by Western blotting using horseradish
peroxidase conjugated polyclonal antibodies against IL-8.
2.4. Proteolytic degradation of IL-8 by vesicle-associated enzymes
The IL-8-77 (5.5 WM) was mixed with native, non-treated vesicles
containing Rgp’s (7 nM) and Kgp (2 nM), or vesicles pretreated with
speci¢c inhibitors, in 200 mM HEPES, 5 mM CaCl2, pH 7.6, with or
without 10 mM cysteine, and incubated at 37‡C. After 30 min the
reaction was stopped by addition of FPRck to a ¢nal concentration of
100 WM. Vesicle pretreatment with either Z-FKck (10 WM), leupeptin
(100 WM), ZFKck+leupeptin, or DIC (100 WM)+E64 (10 WM) was
carried out for 10 min at room temperature in bu¡er containing
10 mM cysteine. The concentration of active gingipain K and gingi-
pains R associated with vesicles was determined by titration with
speci¢c inhibitors, as previously described [25].
2.5. Isolation of human neutrophils
Neutrophils were isolated from the peripheral blood of normal
human volunteers using Percoll density gradient centrifugation [26].
The ¢nal cell suspension contained more than 97% neutrophils, as
measured by Gruºnwald-Giemsa staining, with more than 95% of the
cells being viable by trypan blue exclusion.
2.6. Biological assay of IL-8
Isolated neutrophils were resuspended at 5U106 cells/ml in Hanks’
balanced salt solution and preincubated with cytochalasin B (5 Wg/ml)
for 10 min at 37‡C. Cells were then stimulated with IL-8 (50 ng/ml),
or IL-8 preincubated with gingipains, for 30 min at 37‡C, centrifuged,
and the supernatants tested for neutrophil elastase activity using
MeO-Suc-Ala-Ala-Pro-Val-pNA (625 WM ¢nal concentration) as sub-
strate. The amount of activity released from neutrophils under IL-8
stimulation was calculated as a percentage of total elastase activity in
control cell samples lysed with hexadecytrimethyl ammonium bromide
for 30 min at 37‡C.
2.7. Analysis of IL-8 fragments
Samples of IL-8 were subjected to 16% SDS-Tricine polyacrylamide
gel electrophoresis [27], followed by electroblotting to nitrocellulose
membranes. After incubation for 1 h in a solution of rabbit polyclonal
anti-human IL-8 antibodies (1 Wg/ml), immunoreactive bands were
visualized by incubation for 1 h with goat anti-rabbit antibodies
(1:5000 dilution) conjugated to horseradish peroxidase, followed by
chemiluminescent exposure. For N-terminal sequence analysis pro-
teins were transferred to PVDF membranes, stained with Coomassie
Blue, and bands of interest analyzed.
2.8. Statistical analysis
All assays were performed in triplicate with at least ¢ve di¡erent
neutrophil preparations. Data are expressed as mean þ S.D. For cal-
culation of statistical signi¢cance, the Student’s paired t-test was used,
and a P-value less than 0.01 was considered signi¢cant.
3. Results
3.1. E¡ect of gingipains on IL-8 stimulated degranulation of
neutrophils
The N-terminal fragment of IL-8-77 contains 3 peptide
bonds which may be susceptible to proteolysis by gingipains
(Fig. 1). The cleavage at the ¢rst two bonds Arg5-Ser6 and
Lys8-Glu9 by arginine- (RgpA and RgpB) and lysine-speci¢c
(Kgp) gingipains, respectively, should yield truncated IL-8
with enhanced activity, while the cleavage at the Arg11-Cys12
bond should destroy this cytokine biological activity [28]. To
test this hypothesis a mixture of IL-8-77 with either RgpA,
RgpB or Kgp, incubated for di¡erent time intervals, was as-
sayed for its ability to stimulate neutrophil degranulation
(Fig. 2). After only 5 min incubation all three gingipains en-
hanced IL-8-77 activity to a level characteristic of the 72 res-
idues form. In the cases of RgpA and Kgp prolonged incu-
bation resulted in a progressive decrease in cytokine activity
which was totally lost after 600 min of digestion. In contrast,
treatment of IL-8-77 with RgpB caused a sustained enhance-
ment of activity for at least 60 min and even after 10 h of
incubation the cytokine digest had a signi¢cant ability to stim-
ulate neutrophil degranulation.
3.2. Proteolytic activation of IL-8-77 by individual gingipains
When recombinant IL-8-77 was digested with gingipains at
a molar ratio 550:1 and the reaction mixture analyzed by
immunoblotting, it was found that there was a time-depend-
ent generation of IL-8-derived cleavage products (Fig. 3)
which correlated with the observed changes in IL-8 bioactivity
in the reaction mixtures. At the zero time point only a single
immunoreactive band corresponding to IL-8-77 was observed,
indicating that the cytokine did not undergo degradation dur-
ing boiling in reduced SDS-PAGE treatment bu¡er. After
5 min digestion, however, an immunoreactive band with elec-
trophoretic mobility corresponding to that of IL-8-72 ap-
peared in samples incubated with any of the three gingipains,
and this paralleled the neutrophil stimulating activity found
for the truncated form of IL-8-72 (Fig. 2). Amino-terminal
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Fig. 1. N-terminal amino acid sequence of IL-8-77 with marked
putative cleavage sites for gingipains R (S) and gingipain K (P).
Fig. 2. Elastase release from neutrophils stimulated with gingipains
digest of IL-8-77. RgpA: 95-kDa arginine-speci¢c cysteine protein-
ase, a complex of a 50-kDa catalytic domain with hemagglutinin/
adhesin domains; RgpB: a single chain 50-kDa proteinase; Kgp:
105-kDa lysine-speci¢c proteinase, a complex of a 60-kDa catalytic
domain with hemagglutinin/adhesin domains. The amount of activ-
ity released from neutrophils under IL-8 stimulation was calculated
as a percentage of total elastase activity in control cell samples lysed
with hexadecytrimethyl ammonium bromide for 30 min at 37‡C.
Data are presented as mean þ S.D. *P6 0.01 vs. IL-8-77 control.
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sequence analysis of IL-8-77 cleavage products obtained after
5 or 15 min incubation with either RgpA, RgpB, or Kgp
indicated that its N-terminus was processed at the Arg5-Ser6
and Lys8-Glu9 peptide bonds by Rgp’s and Kgp, respectively.
Incubation of IL-8-77 with Kgp for 60 min yielded two dis-
tinct immunoreactive fragments which di¡ered in molecular
mass but had the same N-terminal sequence (ELRCQ-
CIKTY...). Similarly, two molecular mass IL-8-77 derivatives
with the same N-terminal sequence (SAKELRCQICI...) were
generated when the chemokine was incubated with RgpB for
600 min, both digestions indicating the degradation of the
molecule within the C-terminal region. In contrast to RgpB,
which contains the catalytic domain alone [23], prolonged
digestion with RgpA and Kgp (complexes of individual cata-
lytic and highly homologous hemagglutinin/adhesin domains
[22]), resulted in total IL-8-77 degradation and annihilation of
its neutrophil stimulating activity (Figs. 2 and 3).
3.3. Processing of IL-8-77 by vesicle associated enzymes
In addition to the secretion of soluble enzymes, a signi¢cant
amount of proteolytic activity elaborated by P. gingivalis is
either bound to bacterial cell surfaces or released as outer-
membrane blebs, often referred to as vesicles. Vesicles which
either stay attached to the cell surface or di¡use away into the
periodontal pocket drastically enlarge the bacterial surface
and are considered important virulence factors [29]. In addi-
tion to gingipains [30] they carry other proteolytic enzymes
[25] which may also activate and/or degrade IL-8-77. Thus, we
determined the e¡ect of vesicle-bound proteinases on the ac-
tivity of this chemokine. It was clearly shown that IL-8-77 was
very sensitive to degradation by vesicle-bound proteinases,
and this activity was absolutely dependent on the presence
of reducing agents (Fig. 4), implying a cysteine proteinase(s)
as the chemokine digesting enzyme(s). This observation was
further corroborated by the fact that DIC did not prevent
IL-8 fragmentation, eliminating the possibility of a serine pro-
teinase being involved in this process. Signi¢cantly, E-64 was
also without e¡ect on IL-8 degradation, ruling out the option
of chemokine cleavage by periodontain, a newly described
cysteine proteinase of P. gingivalis which is homologous to
streptopain, because this enzyme activity is strongly inhibited
by this compound (manuscript submitted). All of these data
suggest that vesicle-bound gingipains, which are refractory to
inhibition by DIC and E-64 [22,25,31] and occur at 7 nM
(Rgp’s) and 2 nM (Kgp) concentration in vesicles, are respon-
sible for IL-8 cleavage. Indeed, using vesicles pretreated with
leupeptin and ZFKck, inhibitors speci¢c for Rgp’s and Kgp,
respectively, no degradation occurred, strongly supporting
this conclusion. Moreover, data showing that IL-8 degrada-
tion could be signi¢cantly reduced by leupeptin are again in
support of the hypothesis that vesicle-bound Rgp’s are the
major proteinases responsible for chemokine degradation.
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Fig. 5. Schematic representation of putative compartmentalization
of pro- and anti-in£ammatory reactions to distal and proximal posi-
tions from bacterial plaque induced by a di¡erent range of di¡usion
of soluble and vesicles (small ¢lled circles) associated gingipains.
Fig. 3. Western blot analysis of IL-8-77 after incubation with gingi-
pains.
Fig. 4. Western blot analysis of IL-8-77 after incubation with P.
gingivalis vesicles. 5.5 WM IL-8-77 was digested with vesicles con-
taining 7 nM and 2 nM of Rgp’s and Kgp, respectively. AV: Acti-
vated vesicles alone, or activated and treated with either ZFKck (10
WM), or leupeptin (100 WM), or ZFKck/leupeptin (10 WM/100 WM),
or DIC/E64 (100 WM/10 WM). NAV: Non-activated vesicles.
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4. Discussion
Cytokines are indispensable for the maintenance of both
innate and acquired immunity. Therefore, an understanding
of how bacteria can a¡ect cytokine function at sites of infec-
tion may explain the pathological outcome of many diseases,
including periodontitis [31,32]. In the cytokine network oper-
ating in the periodontium and gingiva a crucial role can be
assigned to chemokines of the CXC family because they are
primarily responsible for the recruitment of neutrophils. These
phagocytic cells are not only involved in periodontal homeo-
stasis [14,33,34], but also in tissue damage, especially if accu-
mulated in excessive numbers and activated to release protein-
ases and oxidants [35,36]. In clinically healthy periodontal
tissue a gradient of IL-8 expression is normally utilized in
directing neutrophils to sites of bacterial colonization [37],
and this low level in£ammation is important in the mainte-
nance of healthy tissue. This balance, however, is apparently
disturbed when products released from subgingival bacterial
plaque trigger fully blown in£ammation, accompanied by
massive in£ux of neutrophils, to form a leukocyte wall which
becomes interposed between the plaque and junctional or
pocket epithelium [14].
Despite neutrophil accumulation in periodontitis sites there
is usually no elimination of infection, and destruction of con-
nective tissue can occur. A growing body of evidence indicates
that a disturbance of the cytokine network by proteolytic
enzymes released by P. gingivalis may contribute to this state.
It has already been shown that proteinases from this perio-
dontopathogen can degrade IL-1L, IL-6 [38,39] and TNFK
[40]. In this report we have presented data which suggest
that P. gingivalis may also signi¢cantly manipulate the normal
recruitment of neutrophils by chemokines through very e⁄-
cient proteolytic processing and activation of IL-8-77 at the
Arg5-Ser6 and Lys8-Glu9 peptide bonds by Rgp’s and Kgp,
respectively. In agreement with previous reports [3,9] the N-
terminus truncated forms of IL-8-72 or IL-8-69 have a 2^3-
fold higher neutrophil activating activity than the parent mol-
ecule. However, IL-8-77 was shown to be very susceptible to
digestion by vesicle-associated gingipains, especially Rgp’s,
and this is an interesting observation since this chemokine is
known to be resistant to both denaturation and proteolytic
degradation by a broad array of host proteinases [9,41], an
apparent physiological adaptation to allow it to operate at
in£ammatory sites rich in oxidants and proteinases.
Signi¢cantly, the degradation and inactivation of IL-8-77
depends on enzyme localization and, evidently, gingipains as-
sociated with bacterial membranes have a profoundly altered
catalytic e⁄ciency, relative to those which are secreted. This
diversity of gingipain activity may have important implica-
tions relative to neutrophil accumulation at infected periodon-
titis sites. Soluble enzymes may be able to di¡use far away
from bacterial plaque and penetrate the periodontal tissues
where they can process IL-8-77 released by epithelial cells,
¢broblasts and keratinocytes, thus enhancing chemokine bio-
logical activity for neutrophils as well as generate C5a, anoth-
er potent chemotactic factor [42,43]. In contrast, vesicle-
bound gingipains with only a limited ability to di¡use from
the plaque surface may destroy the chemotactic gradient
through rapid proteolytic inactivation of IL-8 and, thus, re-
tain neutrophils at a safe distance from subgingival bacterial
plaque. Taking into account that vesicle-associated protein-
ases can also degrade the C5a receptor on neutrophils [44],
we suggest that soluble and vesicle-bound gingipains may play
an important role in protecting bacteria against killing by
neutrophils through the compartmentalization of pro- and
anti-in£ammatory reactions distal and proximal to the bacte-
rial plaque, respectively (Fig. 5).
Recently, it has been reported that invasion of gingival
epithelial cells by P. gingivalis totally inhibits IL-8 production
by these cells in response to a variety of pro-in£ammatory
stimulators [45] and, more importantly, inhibits neutrophil
transepithelial migration [46]. The ability of this organism to
block neutrophil migration across the intact epithelial barrier
and switch o¡ IL-8 production could have a devastating e¡ect
on innate host defence in the periodontium and may play an
important role in the initial stages of infection. However, such
a local chemokine paralysis is apparently overcome once the
subgingival plaque is fully established, because it is known
that large numbers of neutrophils accumulate in periodontal
pockets [13]. Signi¢cantly, P. gingivalis seems to participate
actively in neutrophil in£ux, as there is a signi¢cant correla-
tion between the occurrence of this periodontopathogen and
neutrophil elastase levels in the gingival crevicular £uid at
discrete periodontitis sites [47]. At this stage of the disease
other bacterial defence mechanisms must operate locally to
enable P. gingivalis to £ourish in an environment saturated
with neutrophils, and we suggest that this function is executed
by the anti-in£ammatory activity of membrane- and vesicle-
associated proteinases.
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